CRP and breast cancer: Future research should focus on validating NPAR’s predictive efficacy for BC incidence (rather than prevalence) by conducting prospective cohort studies, exploring models that take into account classical inflammatory markers (e.g., NLR, CRP), and designing intervention trials (e.g., anti-inflammatory therapies or nutritional support) to evaluate its preventive potential.